An expanded commercial peptide facility in India will open to support emerging biotech programmes. 

CDMO Neuland Laboratories will open its new commercial peptide facility in the summer of 2026 at its 17-acre Bonthapally manufacturing campus, with further capacity expansions planned as client demand increases.  

The first of four planned modules is expected to be operational by the summer of this year, adding commercial-scale capabilities to Neuland’s existing clinical stage S-Block facilities.  

Construction of the facility began last year and will enable client execution from small scale to multi-tonne commercial volumes, while also providing the flexibility needed for complex and long chain peptide programs. 

 With GLP-1 manufacturing consuming a growing share of global peptide capacity, Neuland is targeting innovator and emerging biotech programmes facing tightening access to clinical and commercial manufacturing across a broad range of indications. 

“Building on the strength of our reputation among innovator and biotech customers for complex API capabilities, this new facility marks our strategic entry into commercial-scale peptide manufacturing”, said Saharsh Davuluri, Vice Chairman and MD at Neuland Labs. 

“A key part of our strategy will be to first support innovator and emerging biotech companies across all areas of novel peptide development, as well as the ongoing demand for GLP-1 manufacturing.  

“We see commercial peptide production as a key growth driver for the business over the coming years. So we are now scaling rapidly and expect to rollout all modules of the new peptide facility in line with customer demand.”